An imidazopyridine anxiolytic alters glucose tolerance in patients: a pilot investigation.
Clin Neuropharmacol
; 18(1): 79-82, 1995 Feb.
Article
en En
| MEDLINE
| ID: mdl-8665539
ABSTRACT
We have recently shown that compounds with high affinity for peripheral-type benzodiazepine receptors inhibited glucose-induced insulin secretion in vitro. We therefore performed an oral glucose tolerance test in anxious inpatients treated with the imidazopyridine derivative alpidem, which has been shown to display high affinity for these binding sites. The test was performed before and after 1 week of daily administration of the drug. As compared with pretreatment values, a significant alteration of the insulin response to glucose was observed. It is suggested that daily administration of alpidem, at therapeutically effective doses for the treatment of anxiety, may alter glucose tolerance.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Ansiedad
/
Piridinas
/
Ansiolíticos
/
Glucemia
/
Imidazoles
/
Insulina
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Clin Neuropharmacol
Año:
1995
Tipo del documento:
Article
País de afiliación:
Francia